RxDoctor Payments Data

V Parisa Pourzand, MD

Obstetrics & Gynecology · Glendale, CANPI 1548212681

Payments from drug & device makers

$18,844in general payments, 2019–2025

Across 492 payments — averaging $38.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Mimedx Group, Inc.$8K
  • Daiichi Sankyo Inc.$2K
  • AbbVie$1K
  • Pfizer$1K
  • Sumitomo Pharma America, Inc.$922
  • Astellas Pharma US Inc$722
  • plus $5K from 42 others

What the payments were for

  • Consulting fees$8,40045%
  • Food & beverage$9,88852%
  • Education$1321%
  • Other$4252%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$18,844 in reported general payments places this provider in the 95th percentile of 3,784 obstetrics & gynecology providers in California.

See all obstetrics & gynecology providers in California

Medicare billing

Part B allowed, 2024
$313,637
Medicare patients
443
Services billed
2,962

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron185$98,526
MyrbetriqMirabegron122$56,264
PremproEstrogen,con/M-Progest Acet34$10,982
Metronidazole182$8,337
Fesoterodine Fumarate ErFesoterodine Fumarate25$2,020
Nystatin133$1,394
Nystatin-TriamcinoloneNystatin/Triamcinolone Acet39$968
Estradiol14$922
Triamcinolone Acetonide119$747
Fluconazole175$544
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst43$306
Ciprofloxacin Hcl80$166
Misoprostol47$38

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$922$98,526185 claims
Astellas Pharma US IncMyrbetriq$722$56,264122 claims
PfizerPrempro$1,021$10,98234 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,784 obstetrics & gynecology providers in California.

Other obstetrics & gynecology in Glendale

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →